RDInvesting Provides Investors with Free In-Depth Equity Reports on ADSK, AMED, BRKS and CIMT


Follow this company

Companies Mentioned

NASDAQ:ADSK / NASDAQ:AMED / NASDAQ:BRKS / NASDAQ:CIMT
12/03/2013 [ACCESSWIRE]

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

Autodesk, Inc. (NASDAQ: ADSK) shares declined 0.42 percent to close at $45.25 a share Friday. The stock traded between $44.97 and $45.40 on volume of 1.17 million shares traded. Analysts at Thomson Reuters/Verus have recently upgraded the company’s rating to "hold" from "sell". Shares of Autodesk have gained approximately 28.0 percent year-to-date.

Find out more about Autodesk including full access to the free equity report at:     
www.RDInvesting.com/ADSK

Amedisys Inc. (NASDAQ: AMED) shares declined 1.33 percent to close at $16.28 a share Friday. The stock traded between $16.27 and $16.75 on volume of 259,880 shares traded. Analysts at Avondale Partners have recently upgraded the company’s rating to "outperform" from "market perform". Shares of Amedisys have gained approximately 44.0 percent year-to-date.

Find out more about Amedisys including full access to the free equity report at:       
www.RDInvesting.com/AMED

Brooks Automation, Inc. (NASDAQ: BRKS) shares declined 0.56 percent to close at $10.57 a share Friday. The stock traded between $10.55 and $10.75 on volume of 161,736 shares traded. Analysts at Thomson Reuters/Verus have recently upgraded the company’s rating to "buy" from "hold". Shares of Brooks Automation have gained approximately 30.0 percent year-to-date.

Find out more about Brooks Automation including full access to the free equity report at:       
www.RDInvesting.com/BRKS

Cimatron Ltd. (NASDAQ: CIMT) shares declined 1.67 percent to close at $7.05 a share Friday. The stock traded between $6.99 and $7.21 on volume of 63,812 shares traded. Analysts at Thomson Reuters/Verus have recently upgraded the company’s rating to "buy" from "hold". Shares of Cimatron have gained approximately 54.0 percent year-to-date.

Find out more about Cimatron including full access to the free equity report at:     
www.RDInvesting.com/CIMT

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:             
Research Driven Investing         
info@rdinvesting.com

COMMENTS

Leave a comment...
 * 

Your Name
 *